Bharath Rangarajan

Good clinical outcomes following transjugular intrahepatic portosystemic stent‐shunts in Budd–Chiari syndrome

Dhiraj Tripathi, Ross MacNicholas, Chirag Kothari et al. · Alimentary Pharmacology & Therapeutics · 2014 · 105 citations · Full text

Medicine, Surgery, Cardiothoracic Surgery +16

Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care

P. P. Bapsy, Bandana Sharan, Chaitanya Kumar et al. · Cytotherapy · 2014 · 44 citations

Life Sciences, Immunology, Oncology +15

Osteosarcoma journey over two decades in India: Small steps, big changes

Jyoti Bajpai, Arun Chandrasekharan, Vijai Simha et al. · Pediatric Blood & Cancer · 2019 · 16 citations

Medicine, Oncology, Pharmacology +14

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence

Arun Seshachalam, Shashidhar V. Karpurmath, Krishnakumar Rathnam et al. · Journal of Global Oncology · 2019 · 15 citations · Full text

Medicine, Oncology, Pharmacology +17

Key Results of International Randomized Open-Label Clinical Study of BCD-020 (rituximab biosimilar candidate) in Patients with B-Cell Non-Hodgkin’s Lymphoma

Kamil Kaplanov, Andrey Zaritskiy, Sergey Alexeev et al. · Blood · 2014 · 12 citations

Medicine, Oncology, Pharmacotherapy +11